Critically, PLSCR3 knockout in CT26 tumors significantly potentiated the efficacy of anti-PD-1 therapy in vivo, overcoming inherent resistance in this MSS-CRC model. The gene discussed is PLSCR3; the disease is colorectal carcinoma.